智通财经网·2025-08-27 22:30Core Points - The U.S. Department of Health and Human Services has announced the revocation of the emergency use authorization for COVID-19 vaccines, tightening restrictions on Pfizer's vaccine [1] - Moderna's vaccine remains available for children aged 6 months and older, while Pfizer's vaccine is limited to individuals aged 5 and above, and Novavax's vaccine is restricted to those aged 12 and older [1] - The FDA has approved Pfizer's supplemental biologics license application for its vaccine, Comirnaty, specifically for individuals aged 65 and older and those aged 5 to 64 with underlying health conditions [1] Market Reaction - The market response was muted, with Moderna rising by 1.5%, Pfizer increasing by 0.6%, and Novavax gaining 1.07% [2] - The healthcare sector ETF, primarily composed of Pfizer, saw a slight increase [2]